Trevena Inc (TRVN)

[Mr_Simpson72]

TRVN: Currently $1.80

https://finance.yahoo.com/news/drug-approvals-around-corner-trevena-133752100.html

ADCOM: has to be announced 15 days prior to October so any day in next week or following.

PDUFA: FDA announcement November 2nd

Top analyst Ritu Baral at Cowen believes the spotlight here for TRVN moving forward will be on "differentiated safety at AdComm and on label," but she sees a pain management asset tracking for a win in November.

Ultimately, "We expect a positive outcome from the meeting and anticipate broad indication for oliceridine. We anticipate a significant point of discussion of the panel will be the differentiated safety profile of oliceridine, particularly strong trends in the Phase 3 dataset that suggest improved respiratory safety (as well as stat sig improvements in GI tolerability). We think positive discussions and conclusions from the panel could be a major driver for TRVN shares," Baral surmises, liking the odds on oliceridine's approval.

As such, the analyst maintains an Outperform rating on TRVN stock with a $10 price target, which implies a nearly 459% upside from current levels.